Michael Rugaard Jensen

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Hui Gao, Joshua M. Korn, Stéphane Ferretti et al. · Nature Medicine · 2015 · 1.4K citations

Tumor Biology, Radiology, Oncology +10

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

Diego Pasini, Adrian P. Bracken, Michael Rugaard Jensen et al. · The EMBO Journal · 2004 · 876 citations · Full text

Histone Modifications, Chromatin, Transcriptional Regulation +13

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

Vito Guagnano, Pascal Furet, Carsten Spanka et al. · Journal of Medicinal Chemistry · 2011 · 484 citations · Full text

Pharmaceutical Chemistry, Tumor Biology, Medicinal Chemistry +19

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimerski et al. · Breast Cancer Research · 2008 · 222 citations · Full text

Cyclin G Recruits PP2A to Dephosphorylate Mdm2

Koji Okamoto, Hongyun Li, Michael Rugaard Jensen et al. · Molecular Cell · 2002 · 210 citations · Full text

Signal Transduction, Biochemistry, Molecular Pathway +5